186 related articles for article (PubMed ID: 33931953)
21. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
22. Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
Tsamandouras N; Guo Y; Wendling T; Hall S; Galetin A; Aarons L
Pharmacogenet Genomics; 2017 Jan; 27(1):27-38. PubMed ID: 27787353
[TBL] [Abstract][Full Text] [Related]
23. Potential role of the ABCG2-Q141K polymorphism in type 2 diabetes.
Szabó E; Kulin A; Mózner O; Korányi L; Literáti-Nagy B; Vitai M; Cserepes J; Sarkadi B; Várady G
PLoS One; 2021; 16(12):e0260957. PubMed ID: 34855903
[TBL] [Abstract][Full Text] [Related]
24. Uric acid transporters BCRP and MRP4 involved in chickens uric acid excretion.
Ding X; Li M; Peng C; Wang Z; Qian S; Ma Y; Fang T; Feng S; Li Y; Wang X; Li J; Wu J
BMC Vet Res; 2019 May; 15(1):180. PubMed ID: 31146764
[TBL] [Abstract][Full Text] [Related]
25. Functional analysis of SNPs variants of BCRP/ABCG2.
Kondo C; Suzuki H; Itoda M; Ozawa S; Sawada J; Kobayashi D; Ieiri I; Mine K; Ohtsubo K; Sugiyama Y
Pharm Res; 2004 Oct; 21(10):1895-903. PubMed ID: 15553238
[TBL] [Abstract][Full Text] [Related]
26. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
27. Interindividual Regulation of the Breast Cancer Resistance Protein/
Bircsak KM; Moscovitz JE; Wen X; Archer F; Yuen PYS; Mohammed M; Memon N; Weinberger BI; Saba LM; Vetrano AM; Aleksunes LM
Drug Metab Dispos; 2018 May; 46(5):619-627. PubMed ID: 29386232
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers.
Motoki K; Igarashi T; Omura K; Nakatani H; Iwanaga T; Tamai I; Ohashi T
Pharmacol Res Perspect; 2019 Dec; 7(6):e00533. PubMed ID: 31788318
[TBL] [Abstract][Full Text] [Related]
29. Dysfunctional ABCG2 gene polymorphisms are associated with serum uric acid levels and all-cause mortality in hemodialysis patients.
Nakashima A; Ichida K; Ohkido I; Yokoyama K; Matsuo H; Ohashi Y; Takada T; Nakayama A; Suzuki H; Shinomiya N; Urashima M; Yokoo T
Hum Cell; 2020 Jul; 33(3):559-568. PubMed ID: 32180207
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Sugimoto Y; Tsukahara S; Ishikawa E; Mitsuhashi J
Cancer Sci; 2005 Aug; 96(8):457-65. PubMed ID: 16108826
[TBL] [Abstract][Full Text] [Related]
31. Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.
Zou L; Pottel J; Khuri N; Ngo HX; Ni Z; Tsakalozou E; Warren MS; Huang Y; Shoichet BK; Giacomini KM
Mol Pharm; 2020 Mar; 17(3):748-756. PubMed ID: 31990564
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
[TBL] [Abstract][Full Text] [Related]
33. In vitro identification of decreased function phenotype ABCG2 variants.
Suominen L; Sjöstedt N; Vellonen KS; Gynther M; Auriola S; Kidron H
Eur J Pharm Sci; 2023 Sep; 188():106527. PubMed ID: 37451410
[TBL] [Abstract][Full Text] [Related]
34. Identification and functional assessment of BCRP polymorphisms in a Korean population.
Lee SS; Jeong HE; Yi JM; Jung HJ; Jang JE; Kim EY; Lee SJ; Shin JG
Drug Metab Dispos; 2007 Apr; 35(4):623-32. PubMed ID: 17237154
[TBL] [Abstract][Full Text] [Related]
35. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
36. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Hoque KM; Dixon EE; Lewis RM; Allan J; Gamble GD; Phipps-Green AJ; Halperin Kuhns VL; Horne AM; Stamp LK; Merriman TR; Dalbeth N; Woodward OM
Nat Commun; 2020 Jun; 11(1):2767. PubMed ID: 32488095
[TBL] [Abstract][Full Text] [Related]
37. The frequency of rs2231142 in
Alrajeh K; Roman YM
Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
[TBL] [Abstract][Full Text] [Related]
38. Influence of OATP1B1 and BCRP polymorphisms on the pharmacokinetics and pharmacodynamics of rosuvastatin in elderly and young Korean subjects.
Kim Y; Yoon S; Choi Y; Yoon SH; Cho JY; Jang IJ; Yu KS; Chung JY
Sci Rep; 2019 Dec; 9(1):19410. PubMed ID: 31857620
[TBL] [Abstract][Full Text] [Related]
39. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
40. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
